logo
Share SHARE
FONT-SIZE Plus   Neg

Mylan's Generic Version Of Tricor Tablets For Cholesterol Gets FDA Approval

Generic drug maker Mylan Inc. (MYL), Friday said its unit Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application or ANDA for the generic version of Abbvie Inc.'s (ABBV) cholesterol drug Tricor or Fenofibrate.

Mylan said that its unit Mylan Pharmaceuticals Inc. has shipped Fenofibrate Tablets, 48 mg and 145 mg. The drug is prescribed as an adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol, total cholesterol, Triglycerides and apolipoprotein B, and to increase high-density lipoprotein cholesterol in adult patients. Fenofibrate Tablets also are indicated for treatment of adult patients with severe hypertriglyceridemia or high blood levels of triglycerides.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
The recent week marked the lull before the storm, with very few market moving economic numbers released during the week. However, the economic news flow picks up pace in the upcoming week, offering glimpses into every vehicle of economic growth, ranging from consumers to private sector activity to housing.... Life expectancy at birth in the U.S. is already lower than most other developed nations and is now projected to fall further behind by 2030, according to a new study. It also suggests that by 2030, national female life expectancy in South Korea could break the 90 year barrier. Department store chain J.C. Penney Co. Inc. on Friday reported a turnaround to profit in the fourth quarter as a slight decline in sales was more than offset by lower expenses. Adjusted earnings per share for the quarter beat analysts' expectations, while revenues slightly missed their estimates. Earlier today, J.C. Penny announced a plan to optimize its national retail operations.
comments powered by Disqus
Follow RTT